IL3RA and leukemia: Recently, a Phase 1b/2 trial of IMGN632, a CD123-targeting antibody conjugated to an alkyl-benzodiazepine together with azacytidine and venetoclax (Aza/Ven) showed tolerable safety profiles and compelling preliminary anti-leukemia activity (NCT04086264) (32).